Oncotarget: ATM inhibition overcomes resistance to histone deacetylase inhibitor The cover for issue 37 of Oncotarget features Figure 7, "The combination of romidepsin and KU60019 is synergistic ...

Yao, Y., et al. (2024) Epigenetic silencing of BEND4, a novel DNA damage repair gene, is a synthetic lethal marker for ATM inhibitor in pancreatic cancer.

A novel discovery in the field of pancreatic cancer treatment has been unveiled, revealing the epigenetic silencing of BEND4 as a potential synthetic lethal marker for enhancing the efficacy of ...

Article Title. Epigenetic silencing of BEND4, a novel DNA damage repair gene, is a synthetic lethal marker for ATM inhibitor in pancreatic cancer ...

A pivotal finding of this research is the synthetic lethal effect when BEND4 expression is lost in combination with ATM inhibitor treatment. The study showed that PDAC cells with BEND4 methylation ...

A kinase inhibitor blocks the action of protein kinases, which add a phosphate group to a protein in a process called phosphorylation. ... (ATM) inhibitor in the lab.

BERKELEY HEIGHTS, N.J., Nov. 10, 2010 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (Nasdaq:CYCC) (Nasdaq:CYCCP), a biopharmaceutical company developing oral therapies that target the various ...

AZD1390, an ataxia telangiectasia mutant (ATM) kinase inhibitor, demonstrated a manageable safety profile in both recurrent and newly diagnosed glioblastoma (GBM) patients when given in ...

GAITHERSBURG, Md., July 19, 2024 (GLOBE NEWSWIRE) -- Shuttle Pharmaceuticals Holdings, Inc. (Nasdaq: SHPH), (“Shuttle Pharma”), a discovery and development stage specialty pharmaceutical ...

A pivotal finding of this research is the synthetic lethal effect when BEND4 expression is lost in combination with ATM inhibitor treatment. The study showed that PDAC cells with BEND4 methylation ...